Investing.com -- 在两家公司宣布达成最终合并协议后，XOMA Royalty Corporation (NASDAQ:XOMA)股价上涨5%，而Turnstone Biologics (NASDAQ:TSBX)股价跳涨8.4%。
根据交易条款，XOMA将以每股0.34美元现金加一个不可转让的或有价值权(CVR)收购Turnstone。XOMA将于2025年7月11日前开始要约收购，以收购Turnstone所有流通普通股。
在与法律和财务顾问进行全面审查后，Turnstone董事会已一致批准了合并协议。约25.2%的Turnstone股东已经签署支持协议，同意在要约中出售其股份。
要约收购的完成取决于某些条件，包括Turnstone普通股的要约至少占流通股总数的多数、交割时最低现金余额以及其他惯例性交割条件。
要约收购完成后，Turnstone将被XOMA Royalty收购，所有未在要约中出售的剩余股份将转换为获得相同现金和CVR对价的权利。预计交易将于2025年8月完成。
Leerink Partners担任Turnstone的独家财务顾问，Cooley LLP担任法律顾问。Gibson, Dunn & Crutcher LLP担任XOMA Royalty的法律顾问。
本文由人工智能协助翻译。更多信息，请参见我们的使用条款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.